Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI6012 in Stable Coronary Artery Disease
NCT02601560Phase 2Completed
- Sponsor
- MedImmune
- Start
- Dec 2015
- Primary completion
- Aug 2016
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human lecithin-cholesterol acyltransferase in coronary artery disease (CAD), sponsored by MedImmune. Started Dec 2015; status: completed.
02
Drugs
recombinant human lecithin-cholesterol acyltransferase
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT02601560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02601560.